SCHEDULE 13G/A: BlackRock Discloses 5.8% Passive Stake in Dyne Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive beneficial ownership stake in Dyne Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 6,577,879 shares of Dyne Therapeutics, Inc. common stock.
• This represents 5.8% of the total outstanding common shares of Dyne Therapeutics, Inc.
• BlackRock holds sole voting power over 6,487,337 shares and sole dispositive power over 6,577,879 shares.
• The filing is an Amendment No. 2 to Schedule 13G, indicating an update to a previously filed ownership statement.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Dyne Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake. It contains factual information about BlackRock's holding in Dyne Therapeutics, Inc. and does not convey positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The disclosure indicates continued institutional interest in Dyne Therapeutics, Inc. from a major asset manager like BlackRock.
• BlackRock's passive holding suggests a long-term investment perspective rather than an activist stance.

Negatives

• The filing itself does not contain negative information about Dyne Therapeutics, Inc.'s operations or financial performance, as it is a disclosure of ownership.

Risks

• The filing itself does not detail specific risks related to Dyne Therapeutics, Inc.'s operations or financial health. It only states that BlackRock's holding is not for control purposes, which mitigates the risk of an activist investor disrupting management.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Dyne Therapeutics, Inc.'s future performance or outlook, as it is a disclosure of passive ownership.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing reflects a standard disclosure by a large institutional asset manager, BlackRock, Inc., regarding its passive investment in Dyne Therapeutics, Inc. It indicates that Dyne Therapeutics, Inc. remains an investable company for major institutional funds, aligning with broader trends of institutional investment in the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of a significant passive ownership stake by an institutional investor. It does not provide performance metrics for direct comparison to industry standards or specific comparable companies/projects.
• BlackRock's consistent filing of such disclosures across numerous public companies is standard practice for a global asset manager of its size and scope, reflecting its role in managing diversified portfolios for its clients.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially signaling confidence from a major investor.
• Management: Confirms a large, passive institutional investor, which typically implies less direct pressure on management compared to an activist investor.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Dyne Therapeutics, Inc. or BlackRock, Inc. beyond the regulatory filing requirement.

Key Dates

Keywords

BlackRock, Dyne Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Asset Management